Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short interest fell 7.0% in August

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report ) was the beneficiary of a significant drop in short interest in August. As of August 31st, there was short interest totaling 313,000 shares, a decrease of 7.0% from the August 15th total of 336,500 shares. Currently, 1.3% of the company’s shares are short sold. Based on an average daily volume of 63,900 shares, the days-to-cover ratio is currently 4.9 days.

Gyre Therapeutics stock down 1.2%

Shares of GYRE stock opened at $13.87 on Thursday. Gyre Therapeutics has a one year low of $4.80 and a one year high of $30.40. The company’s 50-day simple moving average is $12.95, and its 200-day simple moving average is $13.95.

Gyre Therapeutics (NASDAQ:GYRE – Get Your Free Report ) last posted its earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $25.23 million for the quarter. sell-side analysts anticipate that Gyre Therapeutics will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the transaction, the director now directly owns 1,636 shares of the company’s stock, valued at approximately $19,632. The sale was disclosed in a filing with the SEC, which is accessible through the SEC’s website. 2.92% of shares are held by insiders.

Hedge funds leverage Gyre Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics in the second quarter valued at $166,000. Rhumbline Advisers purchased a new position in shares of Gyre Therapeutics in the second quarter valued at approximately $123,000. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $218,000. Finally, WINTON GROUP Ltd acquired a new stake in Gyre Therapeutics in the second quarter valued at approximately $220,000. 23.99% of shares are currently held by institutional investors.

Gyre Therapeutics Company Profile

(Get a free report)

Gyre Therapeutics, Inc, a biopharmaceutical company, is primarily focused on the development and commercialization of hydronidone for the treatment of steatohepatitis associated with metabolic dysfunction in the United States. Its hydronidone is also being evaluated for the treatment of liver fibrosis in a spectrum of chronic liver diseases.

Further reading

Get news and reviews for Gyre Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gyre Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.